BRD-810

• UNSPSC Description:

  BRD-810 is a highly selective MCL1 inhibitor. BRD-810 can bind to the BH3 groove of MCL1 and block the sequestration of pro-apoptotic proteins, quickly inducing caspase activation in MCL1-dependent cell lines. BRD-810 shows anti-tumor activity in models of blood cancers and solid tumors[1].

• Target Antigen:

  Caspase

• Type:

  Reference compound

• Related Pathways:

  Apoptosis

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/brd-810.html

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C(O)C(N1CCCCO[C@H](CCN2CCOCC2)C3=NN(C)C(CC)=C43)=C(CCCOC5=C6C(C=C(F)C=C6)=CC=C5)C7=C1C4=C(Cl)C=C7

• Molecular Weight:

  703.24

• References & Citations:

  [1]Rauh U, et al. BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models. Nat Cancer. 2024 Aug 23.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2329719-65-3